BIN1 and Alzheimer disease: Results showed that the associations of methylation levels of BIN1 promoter with preclinical AD susceptibility (CN vs. SCD: p = 0.0002; CN− vs. SCD+: p < 0.0001) or CSF biomarkers changes (Table 4) remained significant.